Exploring how interferon lambda helps protect against severe Clostridioides difficile infections
Official title: Investigating the role of interferon lambda in protection against severe Clostridioides difficile infection
Funded at University of Pennsylvania · NIH-11060175 · Data updated 2026-11-12
This study is looking at how a substance called interferon lambda might help protect people from serious infections caused by Clostridioides difficile, which often leads to gut problems in hospitals, and it hopes to find new ways to help heal the gut and improve treatment options for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 15, 2024 |
| Project end | May 14, 2027 |
| Funding year | 2025 |
| Award (this year) | $49,538 |
| NIH project number | 5F31DK138546-02 |
| Project ID | NIH-11060175 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced recurrent Clostridioides difficile infections or are at high risk for such infections.
✕Less likely to help
Patients who have not been diagnosed with Clostridioides difficile infections or those with other unrelated gastrointestinal conditions may not benefit from this research.
What this research studies
This research investigates the role of interferon lambda in providing protection against severe infections caused by Clostridioides difficile, a leading cause of gastrointestinal infections in hospitals. The study focuses on understanding how interferon lambda can stimulate the repair of the intestinal barrier damaged by the bacteria's toxins. By using a specific treatment that activates the immune response, researchers aim to identify the mechanisms through which this protection occurs. Patients may benefit from insights that could lead to new treatment options beyond traditional antibiotics.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that reduce the severity and recurrence of Clostridioides difficile infections.
How similar studies have gone: Previous research has shown promise in using immune modulators like interferon lambda for other conditions, suggesting potential for success in this novel application.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Mears, Kevin Stanton — University of Pennsylvania
- Study coordinator: Mears, Kevin Stanton
Related research
Other NIH-funded projects on the same topics.
-
Understanding how the immune system fights C. difficile to prevent recurrence
A new NIH grant is studying how the body’s own immune response to C. difficile infection might be boosted to prevent future outbreaks.
-
Impact of gut bile acids on C. difficile infection in inflammatory bowel disease
This grant tests whether changes in gut microbes and their bile acids influence how likely people with inflammatory bowel disease are to get and how severe a C. difficile infection could be.
-
Role of gut bacteria in shaping C. difficile infection
Aims to map how the gut microbiome and its metabolic environment influence Clostridioides difficile infection in people and how we might prevent or treat it.
-
Detailed genetic look at C. difficile and the gut microbiome in infection and relapse
Researchers will sequence C. difficile and gut bacteria from thousands of patient stool samples to find genetic and microbial patterns linked to severe or recurring infections.
-
Multivalent vaccine to prevent C. difficile infection and recurrence
This project is developing a vaccine that teaches the immune system to neutralize C. difficile toxins and block the bacteria from coming back for people at risk of infection.
-
Gut-targeted antibiotics for C. difficile infection
Developing gut-targeted antibiotics to kill C. difficile while keeping healthy gut bacteria for people with recurrent C. difficile infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.